You are on page 1of 30

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Program
Time: November 3-6, 2011 Venue: Shenzhen Convention & Exhibition Center (SCEC), China

Registration Time: 08:30-18:00, November 2, 2011 (Wednesday) Place: Room No. 205, 2nd Floor, SCEC Group Photo Time: 08:20-08:40, November 3, 2011 (Thursday) Place: Outside Square, SCEC

Opening Ceremony and Keynote Forum
Opening Ceremony Time: 09:00-09:20, November 3, 2011 (Thursday) Place: Osmanthus Hall, 6th Floor, SCEC Keynote Forum Time: 09:20-11:50, November 3, 2011 (Thursday) Place: Osmanthus Hall, 6th Floor, SCEC Moderator 09:20-09:45 Dr. Zhong Zhong, Senior Director of Discovery Technology, GlaxoSmithKline RD, China Title: From the Structure of the Ribosome to New Antibiotics Dr. Thomas A. Steitz, The Nobel Prize Laureate in Chemistry 2009; Sterling Professor of Molecular Biophysics and Biochemistry, Yale University, USA Title: Form Basic Science to Improved Antibiotics Dr. Ada E.Yonath, The Nobel Prize Laureate in Chemistry 2009; Director of the Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly, Weizmann Institute of Science, Israel Title: The Ubiquitin-proteasome System: From Basic Research to Drug Discovery Dr. Avram Hershko, The Nobel Prize Laureate in Chemistry 2004; Professor, Technion – Israel Institute of Technology, Israel Title: From Dream to Reality in Less Than 10 Years Dr. Rolf G. Werner, Senior Vice President, Corporate Division Biopharmace, Boehringer Ingelheim Gmbh, Germany Title: Targeting RANKL Pathway for Drug Discovery and Development Dr. Scott Simonet, Vice President, Metabolic Disorders Therapeutic Area, Amgen, USA Title: Innovation by Novel and Established Drug Targets Dr. Khusru Asadullah, Head of Global Biomarker, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Germany

09:45-01:10

10:10-10:35

10:35-11:00

11:00-11:25 11:25-11:50

Chapter 1: Drug Discovery Biology
Session 1-1: Systems Biology in Drug Discovery Time: 13:30-15:10, November 3, 2011 (Thursday) Place: Chrysanthemum Hall, 5th Floor, SCEC Session Chair Dr. Ting-Chao Chou, Director, Preclinical Pharmacology Core, Molecular Pharmacology & Chemistry Program, Memorial Sloan-Kettering Cancer Center, USA

009

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

13:30-13:55

13:55-14:20

14:20-14:45

14:45-15:10

Title: Simulation, Imaging and Animal Models for Locoregional Therapeutic Radiopharmaceuticals Development Dr. Franklin Chiu-Leung Wong, Professor of Nuclear Medicine and Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, USA Title: The Mass-Action Law Based Algorithms for Efficient Drug Discovery and Drug Development Dr. Ting-Chao Chou, Director, Preclinical Pharmacology Core, Molecular Pharmacology & Chemistry Program, Memorial Sloan-Kettering Cancer Center, USA Title: G6PD-deficient Cells as Models to Study Pharmacometabolomics Dr. Daniel Tsun-Yee Chiu, Professor and Dean of Research & Development, Chang Gung University, Taiwan Title: Systematic Profiling of the Signal Transduction Network in Rheumatoid Arthritis Dr. Rob Yang, Postdoc Fellow, Department of Systems Biology, Harvard Medical School, USA

Session 1-2: Structural Biology and Drug Discovery Time: 13:30-15:35, November 3, 2011 (Thursday) Place: Rose 1 Hall, 5th Floor, SCEC Session Chair Dr. Michael Hennig, Vice Director & Head, Discovery Technologies, F. Hoffmann-La Roche Ltd., Switzerland Title: Drug Discovery Facilitated by Screening & Biophysical Methods Dr. Michael Hennig, Vice Director & Head, Discovery Technologies, F. Hoffmann-La Roche Ltd., Switzerland Title: Crystal Structure of the Acid-activated Urea Channel from the Human Pathogen Helicobacter Pylori Dr. Hartmut Luecke, Director, Center for Biomembrane Systems, Department of Biochemistry, Biophysics & Computer Science, University of California, USA Title: The Design and Synthesis of Drugs Based on Self-Organizing Quasi-Live Systems Dr. Sonya Sophya Farber, Chief Communications Officer, Noigel, Inc., USA Title: GA-Modified Polymers for Liver Targeting Drug Delivery Dr. Zhi Yuan, Vice Dean, Institute of Polymer Chemistry, Nankai University, China Title: Use of Targeted Library for Efficient Identification of Fragments to Start Medicinal Chemistry Dr. Takaaki Miura, Group Leader, Biostructure Research Group, Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Japan

13:30-13:55

13:55-14:20

14:20-14:45 14:45-15:10 15:10-15:35

Session 1-3: Oncology and Drug Discovery Time: 13:30-17:10, November 3, 2011 (Thursday) Place: Peony Hall, 5th Floor, SCEC Session Chair Co-Chair 13:30-13:55 13:55-14:20 Dr. Rob Howes, R & D Director, Horizon Discovery, UK Dr. Xiaoyan Jiang, Senior Scientist, Terry Fox Laboratory, BC Cancer Research Centre, Canada Title: Development of Antibody-based Therapies for Cancer Dr. Steve Coats, Director of Oncology Research, MedImmune, USA Title: Human ‘Knock-In’ and ‘Kock-Out’ Cell-Lines for Precision Functional Genomics and Targeted Drug Discovery Dr. Rob Howes, R & D Director, Horizon Discovery, UK Title: New Marine Anticancer Agents and Their Mechanisms of Action Dr. Hendrik Luesch, Associate Professor, Department of Medicinal Chemistry, University of Florida, USA

14:20-14:45

010

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

14:45-15:10

Title: Targeting Lipid Signal Required for Cell Cycle Re-entry by Quiescent Cancer Cells Dr. Qihan Dong, Associate Professor, School of Biomedical and Health Sciences, The University of Western Sydney, Australia Coffee Break Title: A Novel Approach to Target an AHI-1-BCR-ABL-JAK2 Interaction Complex in Leukemic Stem Cells Dr. Xiaoyan Jiang, Senior Scientist, Terry Fox Laboratory, BC Cancer Research Centre, Canada Title: 99mTc-MDP Bone Scan as a Molecular Imaging Technique for Diagnostic Studying in Parathyroid tumors, HPT Metabolic Bone Disease and Related Orthopedic Disorders Dr. Jing jing Pen, Professor, Beijing Ji Shui-Tan Hospital, The 4th Clinical Hospital of Peking University, China Title: Do Statins Prevent Oesophageal Cancer? – Evidence from Epidemiology and Its Potential Clinical Implications Dr. Andrew R. Hart, Senior Lecturer in Gastroenterology, The University of East Anglia, UK Title: Design and Synthesis of Modified Resveratrol Analogues Dr. Thet H THET, Lecturer, Jeffrey Cheah School of Medicine and Health Sciences, Monash University (Sunway Campus), Malaysia

15:10-15:30 15:30-15:55

15:55-16:20

16:20-16:45

16:45-17:10

Session 1-4: Neurosciences and Drug Discovery Time: 15:30-17:35, November 3, 2011 (Thursday) Place: Chrysanthemum Hall, 5th Floor, SCEC Session Chair 15:30-15:55 Dr. Pierre A. Guertin, Associate Professor, Laval University, Canada Title: Carbon Nanotubes: Promising Nanovectors for Targeted Intracellular Drug Delivery Dr. Silvana Fiorito, Professor, Department of Clinical Medicine, “Sapienza” University of Rome, Italy Title: Cortical Oscillations in Animal Models of Schizophrenia Dr. Bernat Kocsis, Associate Professor of Psychiatry, Harvard Medical School, USA Title: Translational Research Strategies in Drug Development for Neurodegenerative Disorders Dr. Piu Chan, President and CEO, Wincon TheraCells Biotechnologies Co., Ltd., China Title: Rationale behind the Development of Combination Products in Neurology Dr. Pierre A. Guertin, Associate Professor, Laval University, Canada Title: Early Lesion of The Medial Dorsal Nucleus of the Thalamus Leads to Alterations in Cell Density in the Dentate Gyrus: Possible Animal Model for Schizophrenia Dr. Liesl B. Jones, Biological Sciences and Associate Professor, Lehman College, USA

15:55-16:20 16:20-16:45 16:45-17:10 17:10-17:35

Session 1-5: Molecular Biology and Drug Discovery Time: 13:30-16:20, November 3, 2011 (Thursday) Place: Rose 2 Hall, 5th Floor, SCEC Session Chair Dr. Donna Seto-Young, Director of Endocrinology Laboratory, The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, USA Title: Thiazolidinediones Affect Bone Biomarkers and Osteoblast Growth Independently of Their Effects on Aromatase Dr. Donna Seto-Young, Director of Endocrinology Laboratory, The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, USA

13:30-13:55

011

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

13:55-14:20

14:20-14:45 14:45-15:10

Title: Chain Reaction of Conformational Changes of Ribosomal RNAs and tRNAs Leading to Accuracy in Translation Dr. Kozo Nagano, Professor and Director, Nagano Research Institute of Molecular Biology, Japan Title: How to Use Large Scale Sequence Data from NGS to Understand Genetics and Biology Dr. Kazuho Ikeo, Professor, Center for Information Biology, National Institute of Genetics, Japan Title: The Luminal Environment and Glucose Behavior in the Small Intestine Dr. Toru Takahashi, Associate Professor, Department of Nutrition and Health Science, Faculty of Human Environmental Sciences, Fukuoka Women’s University, Japan Coffee Break Title: MRP1-Targeting Therapy as a New Strategy for Eradication of Resistant Cancer Cells Overexpressing the Multidrug Drug Transporter Dr. Helene Baubichon-Cortay, Assistant Professor, Institute of Biology and Chemistry of Proteins (IBCP), Team Drug Resistance Mechanism and Modulation, UMR 5086 CNRS - University Lyon 1, France Title: Polyadenylation as a Therapeutic Target Dr. Cornelia H. de Moor, Lecturer, RNA Biology, School of Pharmacy, University of Nottingham, UK

15:10-15:30 15:30-15:55

15:55-16:20

Session 1-6: Cell Biology and Drug Discovery Time: 13:30-16:20, November 3, 2011 (Thursday) Place: Rose 3 Hall, 5th Floor, SCEC Session Chair 13:30-13:55 13:55-14:20 Dr. Michael R. Briggs, Senior Director, Biology, Vertex Pharmaceuticals, Inc., USA Title: From the Patient to the Bench to the Patient, A Tumor’S Tale Dr. Michael R. Briggs, Senior Director, Biology, Vertex Pharmaceuticals, Inc., USA Title: FreezFect Cells - HT Nucleofector™ Ready Frozen Primary Cells for HTS/HCS Applications Dr. Konstantin Matentzoglu, Managing Director; External Group Leader, Department of Biology, Trenzyme GmbH, Germany Title: Induction of Neural Differentiation of Mammalian Adipogenic Stem Cells (ASCs), and the Cell Behavior after Transplantation into Mouse Brain Dr. Galina Pavlova, Head, Group of Developmental Genetics and Neurogenetics, Institute of Gene Biology, Russia Title: New Strategies to Tackle Necrotic Cell Death Dr. Ilana Nathan, Associate Professor, Ben-Gurion University and Soroka University Medical Center, Israel Coffee Break Title: Phoretic Motions of Bioparticles Dr. Po-Yuan Chen, Assistant Professor, Department of Biological Science and Technology, China Medical University, Taiwan Title: Characterisation of the Molecular Targets in Leptin-Mediated Renal Tubule Signalling Dr. Andrew J. McAinch, Senior Lecturer Nutrition, Biomedical and Lifestyle Diseases (BioLED) Unit, School of Biomedical and Health Sciences, Victoria University, Australia

14:20-14:45

14:45-15:10

15:10-15:30 15:30-15:55

15:55-16:20

012

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 1-7: Immunology and Drug Discovery Time: 15:55-17:10, November 3, 2011 (Thursday) Place: Rose 1 Hall, 5th Floor, SCEC Session Chair Dr. Sandeep Mukherjee, Associate Professor, Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, USA Title: Novojoint - Smart Cartilage Transplants with Regenerative and Anti-inflammatory Activity Dr. Michael F.G. Schmidt, Professor and Chairman, Institute of Immunology and Molecular Biology, Freie University in Berlin, Germany Title: Treatment of Hepatitis C after Liver Transplantation Dr. Sandeep Mukherjee, Associate Professor, Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, USA Title: Host-pathogen Interaction in Screening for Natural Products with Anti-Infective Activity Dr. Tengku Sifzizul Tengku Muhammad, Dean, Faculty of Science and Technology, University Malaysia Terengganu, Malaysia

15:55-16:20

16:20-16:45

16:45-17:10

Session 1-8: Endocrinology and Drug Discovery Time: 13:30-15:10, November 3, 2011 (Thursday) Place: Room No. 316, 3rd Floor, SCEC Session Chair Co-Chair Dr. Juergen Engel, President & CEO, AEterna Zentaris, Germany Dr. Hua Zhu (David) Ke, Scientific Executive Director, Metabolic Disorders Research, Amgen Inc., USA Title: LHRH Receptors as Targets for Drug Development in Cancer Dr. Juergen Engel, President & CEO, AEterna Zentaris, Germany Title: Development of Novel Drug, Selective Androgen Receptor Modulator (SARM42) with Metabolic Effect, but no Effect on Prostate Dr. Hajime Nawata, President and Director, Fukuoka Prefectural University, Japan Title: Targeting Wnt Signaling in Drug Discovery for Skeletal Diseases Dr. Hua Zhu (David) Ke, Scientific Executive Director, Metabolic Disorders Research, Amgen Inc., USA Title: Stress Release Aldosterone Modulation: Aiming More Than One Target Dr. Milan Radovic, Associate Professor of Internal Medicine, School of Medicine, University of Belgrade, Serbia

13:30-13:55 13:55-14:20

14:20-14:45

14:45-15:10

Session 1-9: Microbiology, Virology and Drug Discovery Time: 13:30-14:45, November 3, 2011 (Thursday) Place: Room No. 314, 3rd Floor, SCEC Session Chair 13:30-13:55 Dr. Jonathan Wong, Defence Scientist, Defence Research and Development Canada Suffield, Canada Title: Development of a Novel “Intracellular Immunization” Strategy to Restrict HIV-1 Infection and Dissemination Dr. Xiaojian Yao, Associate Professor and MMSF Professor, Director, Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada Title: Toll-like Receptor Agonists as Broad-spectrum Antivirals Against Respiratory Viruses Dr. Jonathan Wong, Defence Scientist, Defence Research and Development Canada Suffield, Canada

13:55-14:20

013

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

14:20-14:45

Title: In Vitro HIV-1 Selective Integration into the Target Sequence and Decoy-Effect of the Modified Sequence Dr. Tatsuaki Tsuruyama, Associate Professor, Graduate School of Medicine, Kyoto University, Japan

Session 1-10: Toxicology and Pathology in Drug Discovery Time: 15:05-17:10, November 3, 2011 (Thursday) Place: Room No. 314, 3rd Floor, SCEC Session Chair Dr. Sachin S. Devi, Director, Laboratory of Experimental and Clinical Toxicology; Assistant Professor of Pharmacology, School of Pharmacy, Lake Erie College of Osteopathic Medicine, USA Title: Drugs & Environment – Ecopharmacovigilance Dr. Giampaolo Velo, Professor and Director, Clinical Pharmacology Unit, Veneto Region Pharmacovigilance Centre, Reference Centre for Education and Communication within the WHO Programme for International Drug Monitoring, Italy Title: Lessons from Autoprotection Model to Treat Acute Liver Failure Dr. Sachin S. Devi, Director, Laboratory of Experimental and Clinical Toxicology; Assistant Professor of Pharmacology, School of Pharmacy, Lake Erie College of Osteopathic Medicine, USA Title: Toxicology and Improving Drug Development; A Discussion on Extractables and Leachables Dr. Tamara Fridman, CEO, Vanasyl LLC., USA Title: Detoxification of Organochlorine Compounds by Non-absorbable Dietary Fat Dr. Patrick Tso, Professor, Department of Pathology and Laboratory Medicine, University of Cincinnati, USA Title: Drug Discovery and Personalized Medecine in Cystic Fibrosis and other Misfolding Diseases Dr. Frederic Becq, Professor of Physiology; Director of the Institute of Cellular Physiology and Biology, CNRS/University of Poitiers, France

15:05-15:30

15:30-15:55

15:55-16:20 16:20-16:45

16:45-17:10

Session 1-11: Epidemiology and Biostatistics for Drug Discovery Time: 15:30-17:35, November 3, 2011 (Thursday) Place: Room No. 316, 3rd Floor, SCEC Session Chair Dr. Jerzy E Tyczynski, Director, Epidemiology, Global Surveillance & Pharmacoepidemiology, Global Medical Services, Global Pharmaceutical R & D, Abbott Laboratories, USA Title: The Role of Epidemiology in Evaluating Safety Issues throughout the Drug Development Process Dr. Paul Beninger, Vice President, Global Patient Safety, Genzyme, USA Title: Pharmacoepidemiology Observational Studies in Supporting Patient Safety: Focus on Oncology Therapeutic Area Dr. Jerzy E Tyczynski, Director, Epidemiology, Global Surveillance & Pharmacoepidemiology, Global Medical Services, Global Pharmaceutical R & D, Abbott Laboratories, USA Title: Translating the New Discovery into a Clinical and Commercial Success in the New Health – the Statistical Contribution Dr. Jorgen Seldrup, Senior Director, Centre for Statistics in Drug Development, Quintiles, France Title: Statistical Modeling of Vaccine Safety Dr. Jie Chen, Head of Statistics, Merck Serono, China Title: Clinical Significance in Statistical Hypothesis Testing: A Regulatory Point of View Dr. Chenguang Wang, Assistant Professor, Johns Hopkins University, USA

15:30-15:55

15:55-16:20

16:20-16:45

16:45-17:10 17:10-17:35

014

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 1-12: Pharmacology and Drug Discovery Time: 13:30-16:45, November 4, 2011 (Friday) Place: Room No. 1, 1st Floor, SCEC Session Chair Dr. Parviz Ghahramani, Executive Director; Head of Clinical Pharmacology, Forest Research Institute, USA Title: Early Clinical Discovery in Asia: Challenges and Opportunities Dr. Vincenzo Teneggi, Head of Early Development & Clinical Pharmacology for China and Asia Pacific, pharma Research & Early Development (pRED) China, Roche R & D Center (China) Ltd, China Title: Strategies for Determining Optimal Dosing Regimen for Patients on Dialysis Dr. Parviz Ghahramani, Executive Director; Head of Clinical Pharmacology, Forest Research Institute, USA Title: In Vitro Approaches to Predict Human Adverse Drug Effects Dr. Albert P. Li, President and CEO, In Vitro ADMET Laboratories LLC, USA Title: Cell-based Assay for Drug Research and Development – A Biopharmaceutic Approach Dr. Dongzhou (Jeffery) Liu, Medical Lead and Principle Clinical Investigator, Medical Affairs and Clinical Development, GlaxoSmithKline, USA Coffee Break Title: New Pharmacology and Drug Discovery Leading the World, Combination Drug for Dehydrated Atrophy and Eliminating Lesions Dr. Tam Kuok Leong, Leader, Medicine Multidisciplinary Inventor, New Pfiyer Medicine Studying and Developing International Limited, Macao, China Title: Old Drug, New Use: The Beneficial Effect of Beta-Agonist on Sepsis Therapy Dr. Wen-Jinn Liaw, Professor and Chairman, Department of Anesthesiology, Tri-Service General Hospital, National Defense Medical Center, Taiwan Title: Nebulized Lidocaine Prevents Airway Inflammation, Peribronchial Fibrosis, and Mucus Production in a Murine Model of Asthma Dr. Marco Martins, Head of the Laboratory of Inflammation, Oswaldo Cruz Institute, FIOCRUZ, Brazil

13:30-13:55

13:55-14:20

14:20-14:45 14:45-15:10

15:10-15:30 15:30-15:55

15:55-16:20

16:20-16:45

Chapter 2: Drug Target Discovery and Validation
Session 2-1: Seeking Novel Drug Targets and Trend Time: 08:30-10:10, November 4, 2011 (Friday) Place: Room No. 1, 1st Floor, SCEC Session Chair 08:30-08:55 Dr. Wei Chen, Professor, Department of Pediatrics, University of Minnesota, USA Title: Dopamine D3 Receptor Antagonists as Novel and Effective Anti-Addiction Medications Dr. Eliot Lawrence Gardner, Chief, Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, USA Title: Toll-like Receptors Targeted Therapy of Hematological Malignancies Dr. Wei Chen, Professor, Department of Pediatrics, University of Minnesota, USA Title: State of the Art of Photodynamic Therapy (PDT); Impact on Medicine and Medical Economics: PDT Emerges from the Shadow Dr. Herwig Kostron, Associate Professor for Neurosurgery, Department Neurosurgery, Medical University Innsbruck, Austria

08:55-09:20 09:20-09:45

015

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

09:45-10:10

Title: Jak/Stat1 Pathway as a Target for Tumor Radio and Chemosensitization Dr. Nikolai N. Khodarev, Research Associate Professor, Department of Radiation Cellular Oncology, University of Chicago, USA

Session 2-2: Animal Models as the Tool for Target Validation Time: 10:30-11:20, November 4, 2011 (Friday) Place: Room No. 1, 1st Floor, SCEC Session Chair Dr. Boguslaw Tomanek, Professor and Senior Research Officer, University of Calgary, National Research Council of Canada, Canada Title: Application of Molecular IR and MR Imaging Techniques for Testing of Drug Efficacy Dr. Boguslaw Tomanek, Professor and Senior Research Officer, University of Calgary, National Research Council of Canada, Canada Title: Animal Models for Antidepressants: Future Directions Dr. Franco Borsini, Head, Central & Peripheral Nervous System and General, Italy

10:30-10:55

10:55-11:20

Session 2-3: GPCRs as Effective Drug Targets Time: 08:30-11:20, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC Session Chair Co-Chair 08:30-08:55 Dr. Huailing Zhong, President, U-Pharm Laboratories LLC, USA Dr. Olaf Schroeder, Managing Director, NeuroProof GmbH, Germany Title: Label-free Cell-based Assays for Drug Discovery Dr. Ye Fang, Senior Research Manager, Biochemical Technologies, Science and Technology Division, Corning Incorporated, USA Title: Targeting mGlu2/3 Receptors by Allosteric Modulation for CNS Disorders Dr. Huailing Zhong, President, U-Pharm Laboratories LLC, USA Title: Cyclic Urea as CCR5 Antagonists Dr. Maosheng Duan, VP and Head of Medicinal Chemistry, HD Biosciences (China) Co., Ltd, China Title: Functional Cell Culture Assays in CNS Drug Development Dr. Schroeder Olaf, Managing Director, NeuroProof GmbH, Germany Coffee Break Title: Adrenomedullin and Adrenomedullin Receptor as a Target for Uterine Contraction Inhibitor during Pregnancy Dr. Toshihiko Yanagita, Associate Professor, Department of Pharmacology, Miyazaki Medical College, University of Miyazaki, Japan Title: Genome Driven Target Identification, An Orphan GPCR Approach Dr. Changlu Liu, Research Fellow, Johnson & Johnson Pharmaceutical Research & Development, LLC, USA

08:55-09:20 09:20-09:45

09:45-10:10

10:10-10:30 10:30-10:55

10:55-11:20

Session 2-4: Apoptotic Targets Time: 08:30-09:45, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC Session Chair Dr. W. Gibson Wood, Professor; Director of Graduate Studies, Department of Pharmacology, University of Minnesota School of Medicine, USA

016

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

08:30-08:55

08:55-09:20

09:20-09:45

Title: Statins and Transcriptional Upregulation of the Major Anti-Apoptotic Protein Bcl-2 Dr. W. Gibson Wood, Professor; Director of Graduate Studies, Department of Pharmacology, University of Minnesota School of Medicine, USA Title: Enhancing Paclitaxel-induced Cancer Cell Killing by Antagonizing Bcl-Xl with Navitoclax (ABT-263) Dr. Jue Shi, Assistant Professor, Center for Quantitative Systems Biology, Department of Physics, Hong Kong Baptist University, Hong Kong, China Title: Chemopreventive Effects of Phytochemical Agents on Human Colon Tumor Cells and in a Rat Model of Colon Carcinogenesis Dr. Bousserouel Souad, Researcher, INSERM, Laboratory of Nutritional Cancer Prevention, Faculty of Medicine, University of Strasbourg, France

Session 2-5: Protein Kinase Inhibitors and Protein-Protein Interactions as Drug Targets Time: 10:30-11:20, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC Session Chair Dr. Li Niu, Professor; In-coming Chair, Chemistry Department, The RNA Institute and the Center for Neuroscience Research, State University of New York (SUNY) at Albany, USA Title: Developing RNA Aptamers Against Glutamate Ion Channels Dr. Li Niu, Professor; In-coming Chair, Chemistry Department, The RNA Institute and the Center for Neuroscience Research, State University of New York (SUNY) at Albany, USA Title: Drugs Against Viral Channel Forming Proteins Dr. Wolfgang B. Fischer, Professor, Institute of Biophotonics, School of Biomedical Science and Engineering, National Yang-Ming University, Taiwan

10:30-10:55

10:55-11:20

Chapter 3: Drug Screening Technology
Session 3-1: Quality and Diversity of Libraries of Small-Molecule Compounds Time: 08:30-09:45, November 4, 2011 (Friday) Place: Room No. 4, 1st Floor, SCEC Session Chair Co-Chair 08:30-08:55 Dr. Alexander Volker Mayweg, Head of Discovery Chemistry & Metabolic Chemistry Section; Head of Global Library Workgroup, Roche R & D Center (China) Ltd., China Dr. Zbigniew Pietrzkowski, CSO, Applied BioClinical Inc., USA Title: Quality Diverse Compound Libraries – Are We There yet and Where are We Going: A Roche Perspective Dr. Alexander Volker Mayweg, Head of Discovery Chemistry & Metabolic Chemistry Section; Head of Global Library Workgroup, Roche R & D Center (China) Ltd., China Title: Screening of Natural Products in Human Relevant Systems (HRS) Dr. Zbigniew Pietrzkowski, CSO, Applied BioClinical Inc., USA Title: Quality Control on Tcm Information for Drug Development Dr. William Wei-guo Jia, VP (Research), Shanghai Innovative Research Center of Traditional Chinese, China

08:55-09:20 09:20-09:45

Session 3-2: High-throughput Screening and High-Content Screening in Drug Discovery Time: 08:30-11:45, November 4, 2011 (Friday) Place: Room No. 5, 1st Floor, SCEC Session Chair Dr. Frank Yan, Associate Director; Head of Molecular Design and Biostructure, Deputy Head of Discovery Information, Roche Pharma Research and Early Development China, China

017

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

08:30-08:55 08:55-09:20

09:20-09:45

09:45-10:10

Title: Screening an Ion Channel Library for Safe and Effective Drugs: From HTS to Clinic Dr. Arthur M. "Buzz" Brown, Executive Chairman & CSO, ChanTest Corporation, USA Title: OPI: A Novel Approach for High-throughput Screening Primary Hit Selection Dr. Frank Yan, Associate Director; Head of Molecular Design and Biostructure; Deputy Head of Discovery Information, Roche Pharma Research and Early Development China, China Title: A Time-resolved Biosensor for Drug Screening Dr. Masahide Terazima, Professor, Department of Chemistry, Graduate School of Science, Kyoto University, Japan Title: Comprehensive Multi-omics high-throughput Solutions for Drug R & D Dr. Na Liu, Director, Department of Pharmacogenomics R & D, The Beijing Genomics Institute, China Coffee Break Title: Advanced Discovery Platforms with BacMam Mediated Cellular Assays Dr. Timothy Wong, Market Development Manager, Drug Discovery, Pharma & CRO, Life Technologies, USA Title: Real Time Cell Surface Interaction Analysis: A Focus on Lectin-Cell Glycan Interactions Dr. Zhichao Pei, Professor, College of Science, Northwest A&F University, China Title: Expediting Kinetic Characterization, Epitope Binning and Epitope Mapping of Antibodies Using Label-free Biosensors Dr. Yasmina Abdiche, Associate Research Fellow, Protein Engineering Department, Rinat-Pfizer, USA

10:10-10:30 10:30-10:55

10:55-11:20 11:20-11:45

Session 3-3: Tissue-based Drug Screening Time: 10:30-11:45, November 4, 2011 (Friday) Place: Room No. 4, 1st Floor, SCEC Session Chair 10:30-10:55 10:55-11:20 Dr. Zhanfeng Cui, Scientific Founder, Zyoxel Ltd., UK Title: 3D Perfused Tissue Culture: A Platform for Acute and Chronic Drug Testing Dr. Zhanfeng Cui, Scientific Founder, Zyoxel Ltd., UK Title: Coupling Amperometry and Total Internal Reflection Fluorescence Microscopy for Monitoring Exocytosis of Single Vesicles Dr. Christian Amatore, Director of the Research Unit “PASTEUR”; CNS Full Professor, CNRS, ENS and UPMC, France Title: The Use of a Long Shelf-life in vitro Cell Model of the Human Airway Epithelium (MucilAir™) in Preclinical Drug Development Dr. Samuel Constant, Chief Operating Officer, Epithelix Sàrl, Switzerland

11:20-11:45

Chapter 4: Rational Drug Design
Session 4-1: New Computer-Aided Drug Design Time: 08:30-10:10, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC Session Chair 08:30-08:55 Dr. Jianxin Duan, Senior Applications Scientist, Schrödinger GmbH, Germany Title: Using Semi-Continuum Theory to Aid Drug Discovery and Optimization Dr. Anthony Nicholls, CEO, OpenEye Scientific Software, Inc., USA

018

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

08:55-09:20

09:20-09:45

09:45-10:10

Title: Understanding Ligand Binding Affinity and Specificity through Analysis of Hydration Site Thermodynamics Dr. Jianxin Duan, Senior Applications Scientist, Schrödinger GmbH, Germany Title: Computational Drug-Design Based on the Spatial Structures of the Targeting Proteins Derived from Some Subtypes Dr. Jishou Ruan, Professor of Mathematics and Chair, Department of Probability and Information Theory, College of Mathematical Sciences, University of Nankai, China Title: Role of Waters in Ligand Binding Dr. Art E. Cho, Professor and Chairman, Department of Biotechnology and Bioinformatics, Korea University, Korea

Session 4-2: Fragment-Based Drug Discovery and Ligand-Based Drug Design Time: 11:10-12:00, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC Session Chair 11:10-11:35 Dr. Brian Dymock, Head, Chemistry, S*BIO Pte Ltd., Singapore Title: Discovery of Low Molecular Weight Kinase Inhibitors for Important Pathways in Cancer and Autoimmune Disease Dr. Brian W Dymock, Head, Chemistry, S*BIO Pte Ltd., Singapore Title: Introducing Affinity LC/MS as a Tool for Fragment Screening Dr. Sten Ohlson, Professor, Division of Biochemistry/Biotechnology, School of Natural Sciences, Linnaeus University, Sweden

11:35-12:00

Session 4-3: Targeting Protein Folding and Protein-Protein Interaction Time: 10:30-12:10, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC Session Chair Dr. Borbala Gesser, Associate Professor, Department of Dermatology, Aarhus University Hospital, Denmark Title: Structure-based Design of CXCL12 Inhibitors that Prevent CXCR4 Activation Dr. Yu Chen, Assistant Professor, Department of Molecular Medicine, College of Medicine, University of South Florida, USA Title: Dimethylfumarate Inhibits MIF Induced Proliferation of Keratinocytes by Inhibiting MSK1 and RSK1 Activation and by Inducing Nuclear p-c-Jun (S63) and p-p53 (S15) Expression. Possible Role for Its Anti-Psoriatic Effect Dr. Borbala Gesser, Associate Professor, Department of Dermatology, Aarhus University Hospital, Denmark Title: IL-18 and IL-18BP in Autoimmune Diseases and Poxvirus Infection Dr. Junpeng Deng, Assistant Professor, Department of Biochemistry and Molecular Biology, Oklahoma State University, USA Title: Targeting TNFa with Small Molecule Inhibitors of the TNF-TNFR Interaction Dr. Jessica M. Davis, Assistant Professor, Department of Chemistry & Biochemistry, Fairfield University, USA

10:30-10:55

10:55-11:20

11:20-11:45

11:45-12:10

019

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 4-4: Targeting the Endocannabinoid System Time: 08:30-10:35, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC Session Chair 08:30-08:55 Dr. David F. Woodward, Senior Director, Department of Biological Sciences, Allergan Inc., USA Title: Development of Peripherally Restricted CB1 Antagonists for Treatment of Obesity and Diabetes Dr. Thomas Högberg, Associate Professor and Director, Chemical Research, LEO Pharma A/S, Denmark Title: Identification of Endocannabinoids and Their Cyclo-oxygenase-2 (COX-2) Derived Biosynthetic Products for Use in Glaucoma Dr. David F. Woodward, Senior Director, Department of Biological Sciences, Allergan Inc., USA Title: Cellular Dielectric Spectroscopy: A Cost Effective and Eco-friendly Method for Drug Discovery Dr. Jenny Wang, Senior Scientist, Fatty Acid Amide Program, Allergan Inc., USA Title: Brain Cannabinoid CB2 Receptor Modulates Cocaine’s Actions in Mice Dr. Zheng-Xiong Xi, Associate Scientist, Neuropsychopharmacology Section, Chemical Biology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, USA Title: Endocannabinoid Regulation of Skeletal Muscle Metabolism - Is it still a Target for Obesity and Diabetes? Dr. Andrew J. McAinch, Senior Lecturer Nutrition, School of Biomedical and Health Sciences, Victoria University, Australia

08:55-09:20

09:20-09:45 09:45-10:10

10:10-10:35

Session 4-5: Emerging Enzyme Target Inhibitors Time: 10:55-12:10, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC Session Chair Dr. Nariyoshi Shinomiya, Professor, Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Japan Title: Structure-Based Drug Design Leading to Potent and Selective Irreversible HCV Protease Inhibitors Dr. Deqiang Niu, Associate Director, Avila Therapeutics, Inc., USA Title: Development of Small Molecule Inhibitors for Met, a Receptor Tyrosine Kinase Dr. Nariyoshi Shinomiya, Professor, Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Japan Title: Screening from Nature and Molecular Design of Signal Transduction Inhibitors Active on Inflammation and Cancer Dr. Kazuo Umezawa, Professor of Biochemistry, Chairman, Center for Chemical Biology, Keio University, Japan

10:55-11:20

11:20-11:45

11:45-12:10

Session 4-6: Quantum Methods for Structure-Based Drug Design Time: 08:30-10:10, November 4, 2011 (Friday) Place: Room No. 8, 1st Floor, SCEC Session Chair 08:30-08:55 Dr. Herbert Treutlein, Co-Founder and CEO, Qubist Molecular Design Pty. Ltd., Australia Title: Quantum Mechanical Methods for Fragment-based Design of Malaria Drugs Dr. Herbert R. Treutlein, Co-Founder and CEO, Qubist Molecular Design Pty. Ltd., Australia

020

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

08:55-09:20

09:20-09:45

09:45-10:10

Title: Design and Application of a Novel Scoring Function Based on Semiempirical Quantum Mechanical PM6-DH2X Method Accuratelly Describing Dispersion Energy as well as Hydrogen and Halogen Bonding Dr. Pavel Hobza, Professor of Physical Chemistry, Palacký University, Czech Republic Title: It Moves! Novel Algorithms for Fast and Reliable Molecular Docking. Consideration of Entropic and Quantum Effects Dr. Agnieszka K. Bronowska, Principal Investigator, Heidelberg Institute for Theoretical Studies, Germany Title: Ligand Conformational and Solvation Free Energy in Protein-Ligand Complex Formation Dr. Jindrich Fanfrlik, Postdoctoral Fellowship, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic

Session 4-7: Pharmacophore Methods in Drug Design Time: 10:30-12:10, November 4, 2011 (Friday) Place: Room No. 8, 1st Floor, SCEC Session Chair Dr. János T. Kodra, Head of Department, Protein & Peptide Chemistry 2, Novo Nordisk A/S, Denmark Title: The Use of Pharmacophore Guided Parallel Synthesis for the Discovery of Selective Glucagon Antagonists Dr. János T. Kodra, Head of Department, Protein & Peptide Chemistry 2, Novo Nordisk A/S, Denmark Title: Quasi-live Self-Assembled Supramolecular Drugs for Treatment of Actual Diseases Dr. Sonya Sophya Farber, Chief Communications Officer, Noigel, Inc., USA Title: GRID-based Pharmacophore Elucidation and Virtual Screening Dr. Simon Cross, Senior Scientist and Product Manager, Molecular Discovery Limited, UK Title: Library Design and in Silico Screening Strategy to Identify Drug Candidates for Orphan 7TM Receptors Dr. Thomas Michael Frimurer, Associated Professor, Faculty of Health Sciences, Center for Basic Metabolic Research, University of Copenhagen, Denmark

10:30-11:55

10:55-11:20 11:20-11:45 11:45-12:10

Session 4-8: QSAR and 4D QSAR Based Drug Design Time: 10:30-11:20, November 4, 2011 (Friday) Place: Room No. 9, 1st Floor, SCEC Session Chair Dr. Rumin Zhang, Biophysics Team Lead, In Vitro Pharmacology, Merck Research Laboratories, USA Title: Kinetically Perceptive and Mechanism of Action Informed SAR in Drug Discovery Dr. Rumin Zhang, Biophysics Team Lead, In Vitro Pharmacology, Merck Research Laboratories, USA Title: Involvement of NF-*B in the Suppression of Cyclooxygenase-2 and Apoptosis of A549 Cells Induced by Brucine Dr. Guangwen Shu, Associate Professor, College of Pharmacy, South-Central University, China

10:30-11:55

10:55-11:20

021

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Chapter 5: Leading Drug Discovery Technology
Session 5-1: Lab-On-a-Chip/Microfluidics Time: 13:30-14:20, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC Session Chair 13:30-13:55 13:55-14:20 Dr. Cathy Owen, CEO & President, Nanopoint, Inc., USA Title: Examining the Capabilities of Microfluidics for Drug Screening Applications Mrs. Cathy Owen, CEO & President, Nanopoint, Inc., USA Title: Ion Channel Drug Screening Platform: A Planar Patch-Clamp Chip Integrated with OnDemand Solution Generation Dr. De-Shien Jong, Associate Professor, National Taiwan University, Taiwan

Session 5-2: MS, LC-MS in Drug Discovery Time: 13:30-14:45, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC Session Chair 13:30-13:55 13:55-14:20 14:20-14:45 Dr. Wulff Niedner, Manager, LC Products, Thermo Fisher Scientific, Germany Title: LC-MS/MS Assays for Peptides and Proteins in Drug Discovery and Development Dr. Jaap Wieling, Vice President, Bioanalysis and Technology R&D, QPS, The Netherlands Title: Towards Standard-free Quantitative and Qualitative Analysis in Liquid Chromatography Dr. Wulff Niedner, Manager, LC Products, Thermo Fisher Scientific, Germany Title: Comprehensive Quantitative and Qualitative Liquid Chromatography–Radioisotope–Mass Spectrometry Analysis for Safety Testing of Tolbutamide Metabolites without Standard Samples Dr. Zenzaburo Tozuka, Research Fellow and Scientific Adviser, ADME & Tox. Research Institute, Sekisui Medical Co., LTD., Japan

Session 5-3: NMR and In Vivo MR Techniques in Drug Discovery Time: 15:30-17:10, November 4, 2011 (Friday) Place: Room No. 2, 1st Floor, SCEC Session Chair 15:30-15:55 15:55-16:20 16:20-16:45 Dr. Jun Hu, Senior NMR Spectroscopist, AstraZeneca, USA Title: Modern NMR Applications in Drug Discovery Dr. Jun Hu, Senior NMR Spectroscopist, AstraZeneca, USA Title: Observed = Quantified: Validations and Applications of Universal NMR Quantitation Methods Dr. Huaping Mo, Associate Director, Shanghai Institute of Organic Chemistry, China Title: Automated NMR in Fragment Based Lead Discovery Dr. Ke Ruan, Associate Professor, School of Life Science, University of Science and Technology of China, China Title: In vivo MR Measurement of Refracative Index and T2 Relaxation Time with Clinical Application to Discriminate Various Brain Lesions Noninvasively Dr. Tapan K. Biswas, Radiologist & Rsearcher, Biswas X Ray & Scan Centre, India

16:45-17:10

022

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 5-4: X-Ray and Crystallography in Drug Discovery Time: 13:30-17:10, November 4, 2011 (Friday) Place: Room No. 4, 1st Floor, SCEC Session Chair Co-Chair 13:30-13:55 13:55-14:20 Dr. Richard Pauptit, Associate Director and Principal Scientist, Global Structural Chemistry AstraZeneca, UK Dr. Bob B. He, Director of Innovation and Business, Development-XRD2, Bruker AXS Inc., USA Title: Structural Biology in the Disocvery of Diabetes Protein Therapeutics Dr. Gerd Schluckebier, Team Leader, Structural Biology, Novo Nordisk A/S, Denmark Title: Crystallography and Biopharmaceuticals Dr. Richard A. Pauptit, Senior Principal Scientist; Discovery Enabling Capabilities and Sciences, AstraZeneca, UK Title: Structure-based Design of New Generation Anticoagulants Dr. Herbert Nar, Director Structural Research, Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany Title: Providing Electron Density From High Resolution X-Ray Data as Complementary Information to Drug Development Dr. Peter Luger, Professor, Institute for Chemistry Crystallography, Free University Berlin, Germany Coffee Break Title: Two-Dimensional X-Ray Diffraction for Pharmaceutical Dr. Bob B. He, Director of Innovation and Business, Development-XRD2, Bruker AXS Inc., USA Title: Expecting the Unexpected: Ligand-Induced Conformational Changes of Drug Targets Revealed by Protein Crystallography Dr. Xin Chen, Principal Research Investigator, Sanofi-Aventis, USA Title: Better Data with PILATUS detectors Dr. Clemens Schulze-Briese, CSO, Dectris Ltd., Switzerland Title: Inclusion Complexes and Co-crystals of Calixarenes with Drug Molecules - A Possible New Forms of Pharmaceuticals Dr. Kinga Suwinska, Associate Professor, Institute of Physical Chemistry, Polish Academy of Sciences, Poland

14:20-14:45

14:45-15:10

15:10-15:30 15:30-15:55 15:55-16:20

16:20-16:45 16:45-17:10

Session 5-5: Biomarker Methods in Drug Discovery and Development Time: 13:30-14:20, November 4, 2011 (Friday) Place: Room No. 5, 1st Floor, SCEC Session Chair Dr. Khusru Asadullah, Head of Global Biomarker, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Germany Title: Biobanking as an Integrated Part of Biomarker Research Dr. Khusru Asadullah, Head of Global Biomarker, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Germany Title: Human Primary Tumor Model Platform for Oncology Drug Discovery Dr. Danyi Wen, Vice President, Biology, External Collaboration & Business Development, IACUC Chairman, Shanghai ChemPartner, Co. Inc., China

13:30-13:55

13:55-14:20

023

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 5-6: Molecular Imaging Technology Time: 15:30-16:45, November 4, 2011 (Friday) Place: Room No. 3, 1st Floor, SCEC Session Chair 15:30-15:55 Dr. Zhong Zhong, Senior Director of Discovery Technology, GlaxoSmithKline RD, China Keynote Speech Title: From the Cell to the Animal to the Human - Translational NIR Biomarker Imaging Dr. Jacob G. Tesdorpf, Director Imaging Platforms, PerkinElmer, USA Title: Cell Imaging Assays in Drug Discovery Dr. Zhong Zhong, Senior Director of Discovery Technology, GlaxoSmithKline RD, China Title: Molecular Imaging in Drug Delivery and Drug Discovery Dr. Rao Papineni, Distinguished Scientist and Senior Principal Investigator, Research and Development, Carestream Molecular Imaging, USA

15:55-16:20 16:20-16:45

Session 5-7: Phage Display in Drug Discovery Time: 13:30-14:45, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC Session Chair Dr. Chung-Ming Hsieh, Associate Director, Antibody Generation Group, Abbott Bioresearch Center, USA Title: Antibody Discovery and Engineering by mRNA and Yeast Displays, A Powerful Combination Dr. Chung-Ming Hsieh, Associate Director, Antibody Generation Group, Abbott Bioresearch Center, USA Title: Peptide Phage Display as a Tool for Identification of Vectors for Targeted Diagnostic Imaging Dr. Astrid Hilde Myrset, CEO of Omegatri AS, Norway Title: Molecular Signature-recognizing Peptides: Discovery and Uses for Imaging and Drug Delivery Dr. Byung-Heon Lee, Associate Professor, Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Korea

13:30-13:55

13:55-14:20 14:20-14:45

Session 5-8: Bioinformatics, Computational Biology and Chemoinformatics Time: 13:30-14:20, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC Session Chair Dr. Hugo Geerts, Chief Scientific Officer, In Silico Biosciences; Adj Associate Professor, School of Medicine, University of Pennsylvania, USA Title: Integration not Isolation: The Role of Systems Pharmacology in Drug Discovery and Development Dr. Balaji Agoram, Director, Clinical Pharmacology/DMPK, MedImmune, UK Title: Re-engineering CNS Drug R & D Using Computer-Based Mechanistic Modeling and Simulation Dr. Hugo Geerts, Chief Scientific Officer, In Silico Biosciences; Adj Associate Professor, School of Medicine, University of Pennsylvania, USA

13:30-13:55 13:55-14:20

024

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Chapter 6: Frontier in Small Molecule Drug Discovery
Session 6-1: Frontier in Small Molecule Drug Discovery Time: 13:30-16:45, November 4, 2011 (Friday) Place: Room No. 8, 1st Floor, SCEC Session Chair Co-Chair Dr. Jin Li, Director of Global Compound Sciences, AstraZeneca PLC, UK Dr. Mark A Myers, Program Coordinator and Lecturer in Biomedical Science, School of Health Sciences, University of Ballarat, Australia Title: Novel Approaches to Discovering Ligands for GPCRs Dr. Jin Li, Director, Global Compound Sciences, DECS Lead Generation, AstraZeneca R & D, UK Title: Identification of Novel Peptide Agonists for a G Protein Coupled Receptor from a Random Peptide Library Dr. Shigeki Takeda, Professor, Department of Chemical Biology, Gunma University Graduate School of Engineering, Japan Title: Anticancer Bioactive Peptide Potentiates Cisplatin Chemotherapy Efficacy and Improves the Quality of Life in Xenografted Nude Mice Bearing Human Gastric Cancer Dr. Xiulan Su, Director, Clinical Research Center of Affiliated Hospital, Inner Mongolia Medical College, China Title: In Silico Search and Syntheis of Flavin Analogs as Protein Kinase Inhibitors and Antitumor Activities Dr. Tomohisa Nagamatsu, Associate Professor & Head, Department of Molecular Pharmaceutical Chemistry, Okayama University, Japan Coffee Break Title: Zinc Chelation and Insulin Hexamer Dispersal by Peptides Dr. Mark A Myers, Program Coordinator and Lecturer in Biomedical Science, School of Health Sciences, University of Ballarat, Australia Title: Selective Inhibitors for the Integrins *v*3 and *5*1 and Their Use in Medicine Dr. Horst Kessler, Carl von Linde Senior Fellow, Department of Chemistry, Institute for Advanced Study, Technical University of Munich, Germany Title: Identification of New GATA4-small Molecule Inhibitors by Structure-based Virtual Screening Dr. Georges Nemer, Associate Professor, Department of Biochemistry and Molecular Genetics, American University of Beirut, Lebanon

13:30-13:55 13:55-14:20

14:20-14:45

14:45-15:10

15:10-15:30 15:30-15:55

15:55-16:20

16:20-16:45

Chapter 7: Breaking Biotherapy Discovery and Development
Session 7-1: Protein Therapeutics Time: 15:30-17:10, November 4, 2011 (Friday) Place: Room No. 5, 1st Floor, SCEC Session Chair Co-Chair Dr. Alexey M. Kopylov, Professor, Chemistry Department and Institute of Physico Chemical Biology, Moscow State University; Apto-Pharm Ltd, Russia Dr. Girish J. Kotwal, Professor of Biochemistry and Microbiology, University of Medicine and Health Sciences, St. Kitts Title: RNA Aptamer: The Next Generation of Cancer Stem Cell-targeted Molecular Imaging Dr. Wei Duan, Professor, School of Medicine, Deakin University, Australia Title: Anticoagulant Activity of Thrombin-binding DNA Aptamers Dr. Alexey M. Kopylov, Professor, Chemistry Department and Institute of Physico Chemical Biology, Moscow State University; Apto-Pharm Ltd, Russia

15:30-15:55 15:55-16:20

025

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

16:20-16:45

16:45-17:10

Title: Vaccinia Virus Compliment Control Protein, a Protein Therapeutic for Controlling Inflammation in Alzheimer’s Disease, Arthritis, Atherosclerosis, Cns Injury and Number of Other Diseases Dr. Girish J. Kotwal, Professor of Biochemistry and Microbiology, University of Medicine and Health Sciences, St. Kitts Title: Rational Improvement of Aptamers to Gain Therapeutics Value. Problems and Solutions Dr. Golovin Andrey, Molecular Biologist, Lomonosov Moscow State University, Russia

Session 7-2: Vaccine Innovation & Biotherapy Time: 15:05-17:10, November 4, 2011 (Friday) Place: Room No. 6, 1st Floor, SCEC Session Chair Co-Chair Dr. Bernd Eisele, CEO, Vakzine Projekt Management GmbH, Germany Dr. Matthew Sleeman, Director of Biology, Respiratory, Inflammation and Autoimmunity Group (RIA), UK Title: Tuberculosis: Improved Immunogenicity after Vaccination with the Live Recombinant Vaccine VPM1002 in Phase I Clinical Trials Dr. Bernd Eisele, CEO, Vakzine Projekt Management GmbH, Germany Title: Novel IgE/cytokine Peptide-based Virus-like Particle Vaccines for Treatment of Allergic and Autoimmune Diseases Dr. Zhikang Peng, Professor, Department of Pediatrics and Child Health, Department of Immunology, University of Manitoba, Canada Title: Mavrilimumab, A Novel Anti GMCSFR Alpha Antibody Targeting Macrophages in Rheumatoid Arthritis Dr. Matthew Sleeman, Director of Biology, Respiratory, Inflammation and Autoimmunity Group (RIA), UK Title: From Discovery in Academic Setting to Administration in Humans – Developing Therapeutic Antibodies Against Rare Diseases Dr. Dimiter S Dimitrov, Senior Investigator, NCI, NIH, USA Title: Quadrivalent HPV 6/11/16/18 Vaccine Efficacy against Cervical and External Genital Disease in Subjects with Prior Vaccine HPV Type Infection Dr. Sven-Eric Olsson, Associate Professor, Karolinska Institute at Danderyd Hospital, Sweden

15:05-15:30

15:30-15:55

15:55-16:20

16:20-16:45

16:45-17:10

Session 7-3: Immunotoxin Time: 15:30-17:10, November 4, 2011 (Friday) Place: Room No. 7, 1st Floor, SCEC Session Chair 15:30-15:55 15:55-16:20 Dr. Gabriel Lasala, President, TCA Cellular Therapy, USA Title: Combination Stem Cell Therapy for Severe Limb Ischemia Dr. Gabriel Lasala, President, TCA Cellular Therapy, USA Title: Reversal of Type 1 Diabetes through the Immune Modulation of Cord Blood-Derived Multipotent Stem Cells in Humans Dr. Yong Zhao, Assistant Professor, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, USA Title: Antibody-Based Fusion Proteins to Target Death Receptors in Cancer Dr. Edwin Bremer, Assistant Professor, Department of Surgical Research Laboratory, University Medical Center Groningen, The Netherlands Title: Therapeutic Attenuation of Silica-Induced Pulmonary Fibrosis by Immunotoxin Chimeric Molecule il-13pe Dr. Patrícia Martins, Senior Researcher, Laboratory of Inflammation, Oswaldo Cruz Foundation, Brazil

16:20-16:45

16:45-17:10

026

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Chapter 8: Genome-Based Drug Discovery and Development
Session 8-1: Genome-Based Drug Discovery and Development Time: 08:30-11:45, November 5, 2011 (Saturday) Place: Room No. 1, 1st Floor, SCEC Session Chair Co-Chair Dr. Paolo Mascagni, Director of Preclinical R & D, Italfarmaco Spa, Italy Dr. Carsten Rosenow, Associate Director, Global Market, Development of Genotyping, Illumina, Inc., USA Title: Dried Blood Spot Sampling in Drug Development Studies for Pharmacokinetics, Pharmacogenomics and Safety Assessments Dr. Jaap Wieling, Vice President, Bioanalysis and Technology R & D, QPS, The Netherlands Title: Understanding Health and Disease Through Genomic Research: New Drug Target Discovery Utilizing Array and Sequencing Technology Dr. Carsten Rosenow, Associate Director, Global Market, Development of Genotyping, Illumina, Inc., USA Title: A New Toolbox in Functional Proteomics •Getting a Focused Picture of Drug Action• Dr. Friedrich Kroll, Head, Medicinal Chemistry, Caprotec Bioanalytics GmbH, Germany Title: Gene Therapy for Glaucoma: Insights into the Pharmacology of the Future Dr. Paul L. Kaufman, Professor & Chair, Department of Ophthalmology & Visual Sciences, School of Medicine & Public Health, University of Wisconsin-Madison, USA Coffee Break Title: The Pleotropic Activity of HDAC Inhibitors from Auto-immunity to Cancer to Neurodegenerative Disorders Dr. Paolo Mascagni, Director of Preclinical R & D, Italfarmaco Spa, Italy Title: Application of Metabolomics in Preclinical Toxicology Studies Dr. Yutai Li, Research Fellow, Merck, USA Title: Targeted Alpha Therapy for Cancer Dr. Graeme Melville, Senior Researcher, Centre for Radiation Oncology, St George Hospital, Australia

08:30-08:55

08:55-09:20

09:20-09:45 09:45-10:10

10:10-10:30 10:30-10:55

10:55-11:20 11:20-11:45

Chapter 9: Traditional Chinese Medicine vs Natural Product based Drug Discovery
Session 9-1: Traditional Chinese Medicine vs Natural Product based Drug Discovery Time: 08:30-11:20, November 5, 2011 (Saturday) Place: Room No. 2, 1st Floor, SCEC Session Chair Dr. Cory J. Xian, Professor of Bone Research & NHMRC Senior Research Fellow, Bone Growth and Repair Research Group, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Australia Title: Antioxidant and Oxidative Activity, Composition and Functionalities of Whole Coffee Fruits and Their Extract Dr. Boris Nemzer, Director of Research and Development, FutureCeuticals, Inc., USA Title: Nutraceuticals for Preventing Bone Loss Following Cancer Chemotherapy Dr. Cory J. Xian, Professor of Bone Research & NHMRC Senior Research Fellow, Bone Growth and Repair Research Group, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Australia

08:30-08:55

08:55-09:20

027

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

09:20-09:45

09:45-10:10

Title: Natural Compounds that Stimulate Bone and Periodontal Tissue Formation - Harmine, Acerogenins and Honokiols Dr. Je Tae Woo, Professor, Biological Chemistry Department, College of Bioscience and Biotechnology, Chubu University, Japan Title: Study on Effects and Mechanisms of Compatibility of Periplocin and Panax Notoginseng Saponin Dr. Han Zhang, Assistant Research Fellow, Tian Jin University of Traditional Medicine, China Coffee Break Title: The Anti-Tumor Effects of Flavonoids from the Ethnic Medicine Docycia Delavayi (Franch) Schneid and its Possible Mechanism Dr. Xukun Deng, Associate Professor, College of Pharmacy, South-Central University, China Title: Potential Medicinal Plants for Diabetes and Obesity Dr. Vikas Kumar, Reader in Pharmacology, Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, India

10:10-10:30 10:30-10:55

10:55-11:20

Chapter 10: Pipeline Update on IND against Major Diseases
Session 10-1: Cardiovascular Diseases Time: 08:30-09:45, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC Session Chair Dr. Kewei Wang, Professor and Chair, Peking University School of Pharmaceutical Sciences; Professor of Neurobiology, Peking University School of Medicine, China Title: Domestic and Miniature Swine as Models in Toxicology and Drug Discovery Dr. Michael Swindle, Professor, Department of Comparative Medicine, Medical University of South Carolina, USA Title: Preclinical Cardiovascular Safety Models Dr. Michael Markert, Principal Scientist, Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany Title: Synthesis, Screening and Biological Activity of Novel Kv7/Kcnq/M-Channel Modulators for Neuropsychiatric Disorders Dr. Kewei Wang, Professor and Chair, Peking University School of Pharmaceutical Sciences; Professor of Neurobiology, Peking University School of Medicine, China

08:30-08:55

08:55-09:20

09:20-09:45

Session 10-2: Neurodegenerative Diseases Time: 08:30-11:45, November 5, 2011 (Saturday) Place: Room No. 4, 1st Floor, SCEC Session Chair Co-Chair 08:30-08:55 08:55-09:20 Dr. Ratan Bhat, Director and Head of Portfolio Enhancement, AstraZeneca Research and Development, Innovative Medicines CNS & Pain, Sweden Dr. Yves P. Auberson, Executive Director, Novartis Institutes for BioMedical Research, Switzerland Title: Bace1 Inhibitors for the Treatment of Alzheimer’s Disease Dr. Johanna Fälting, iMed Project Director, AstraZeneca Research and Development, Sweden Title: Targeting Tau in Alzheimer´s Disease Dr. Ratan Bhat, Director and Head of Portfolio Enhancement, AstraZeneca Research and Development, Innovative Medicines CNS & Pain, Sweden

028

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

09:20-09:45 09:45-10:10

Title: Ryanodine Receptor III as a Target of Drug Design for Neurodegeneration Dr. Kenneth T. Wann, Professor, Welsh School of Pharmacy, Cardiff University, UK Title: BGG492, A Competitive AMPA/Kainate Antagonist in Clinical Development for the Treatment of Epilepsy Dr. Yves P. Auberson, Executive Director, Novartis Institutes for BioMedical Research, Switzerland Coffee Break Title: Functionalized Magnetonanoparticles in Visualization of Function and Disease on MRI Dr. Massoud Akhtari, Professor, University of California, Los Angeles Health System, USA Title: Pharmacogenomic Approaches to Neuroprotection Dr. Z. Carl Lin, Assistant Professor, McLean Hospital, Harvard Medical School, USA Title: New Paradigm Drug Design, Catalytic Drug on Amyloidogenic Diseases Dr. Keunhong Jeong, Assistant Professor, Department of Chemistry, Korea Military Academy, Korea

10:10-10:30 10:30-10:55 10:55-11:20 11:20-11:45

Session 10-3: Mental Disease Drug Discovery Time: 10:05-12:10, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC Session Chair 10:05-10:30 10:30-10:55 10:55-11:20 11:20-11:45 11:45-12:10 Dr. Roumen Milev, Professor of Psychiatry and Psychology; Head, Queen’s University, Canada Title: Deep Lung Delivery of Inhaled Pure Nicotine for Smoking Cessation Dr. Igor Gonda, CEO and President, Aradigm Corporation, USA Title: Sleeping Problems in Neuropsychiatric Disorders Dr. Taina Nieminen-von Wendt, CEO, NeuroMental, Finland Title: Is There a Role of Polysomnogram (PSG) in the Evaluation of Drugs for Mood Disorders? Dr. Roumen Milev, Professor of Psychiatry and Psychology; Head, Queen’s University, Canada Title: Neu-P11: A Novel Melatonin-Serotonin Agonist for the Treatment of Insomnia Dr. Moshe Laudon, Director, Drug Discovery, Neurim Pharmaceuticals Ltd., Israel Title: Stress Biomarkers' Associations to Pain in the Neck, Shoulder and Back in Healthy Media Workers: 12-Month Prospective Follow-up Dr. Elisabet Schell, Lecturer and Superviser, Department of Molecular Medicine and Surgery, Karolinska Institutet, Sweden

Session 10-4: Diabetes & Other Metabolic Diseases Session 10-4-1: Diabetes Drug Discovery and Therapy Time: 08:30-12:10, November 5, 2011 (Saturday) Place: Room No. 5, 1st Floor, SCEC Session Chair Co-Chair Dr. Lily Stojanovska, Associate Head, School of Biomedical and Health Sciences, Faculty of Health, Engineering and Science, Victoria University, Australia Dr. Chris Triggle, Professor, Departments of Medical Education and Pharmacology, Weill Cornell Medical College in Qatar, Qatar Title: Gestational Diabetes AKA Type 2 Diabetes Dr. Lisa E Moore, Chief of the division of Maternal Fetal Medicine, University of New Mexico, USA Title: The Role of Insulin Sensitizers in the Management of Insulin Resistance and Type 2 Diabetes Dr. Lily Stojanovska, Associate Head, School of Biomedical and Health Sciences, Faculty of Health, Engineering and Science, Victoria University, Australia

08:30-08:55

08:55-09:20

029

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

09:20-09:45

09:45-10:10

Title: Two Important Discoveries Dr. Luc F. Van Gaal, Professor of Medicine, Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Belgium Title: A Novel AMPK Activator Based from Natural Products Dr. Wei Wu, General Manager, Hainan Deze Drug Research Co., Ltd, China Coffee Break Title: Protecting the Endothelium Dr. Chris R Triggle, Professor, Departments of Medical Education and Pharmacology, Weill Cornell Medical College in Qatar, Qatar Title: Ginsenoside Rb1: A Novel Antiobesity and Antihyperglycemic Compound Dr. Min Liu, Associate Professor, College of Medicine, University of Cincinnati, USA Title: Bile Acid Metabolism for the Control of Metabolic Syndrome Dr. Mitsuhiro Watanabe, Associate Professor, Department of Internal Medicine, Keio University, Japan Title: Pharmacogenomics of Pioglitazone Dr. Sandeep K Mathur, Professor, Department of Endocrinology, S.M.S. Medical College, India

10:10-10:30 10:30-10:55

10:55-11:20 11:20-11:45

11:45-12:10

Session 10-4: Diabetes & Other Metabolic Diseases Session 10-4-2: Diabetes Related Metabolic Complications and Other Metabolic Diseases Time: 08:30-11:20, November 5, 2011 (Saturday) Place: Room No. 6, 1st Floor, SCEC Session Chair Dr. Sudarshan Ramachandran, Consultant Biochemist, Department of Biochemistry, Good Hope Hospital NHS Trust, UK Title: Pharmacotherapy for Weight Management – A Past, Present, but still a Future? Dr. Andrew Hartland, President, Pathology Section of the Royal Society of Medicine; UK Senior Lecturer, Division of Medicine, University of Birmingham, UK Title: Interesting Observations in HDL-cholesterol and Creatinine Levels Following Fibrate and Glitazone Use in a Real World Metabolic Clinic Dr. Sudarshan Ramachandran, Consultant Biochemist, Department of Biochemistry, Good Hope Hospital NHS Trust, UK Title: The Clock Genes. A New Approach for the Treatment of Obesity and Type II Diabetes Dr. Daniela Jakubowicz, Professor of Medicine & Endocrinology, Virginia Commonwealth University, USA; Professor of Medicine VCU, Wolfson Hospital University of Tel Aviv, Israel Title: The Progress of Pharmacotherapy on Diabetic Retinopathy Dr. Xinyuan Zhang, Professor, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, China Coffee Break Title: Hypoglycemia: A Possible Link between Insulin Resistance and the Metabolic Syndrome Dyslipidemia Dr. Myriam CristinaYafar Ensling, Assistant professor, Center for Health Care Quality, University of Missouri-Columbia, USA Title: Targeting SREBP-1 Regulated Lipid Metabolism to Treat Cancer Dr. Deliang Guo, Assistant Professor, Department of Radiation Oncology, James Comprehensive Cancer Center, The Ohio State University Medical Center, USA

08:30-08:55

08:55-09:20

09:20-09:45

09:45-10:10

10:10-10:30 10:30-10:55

10:55-11:20

030

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 10-5: Severe Respiratory and Inflammation Diseases Session 10-5-1: Drug Discovery Targeting Asthma and Chronic Obstructive Pulmonary Disease (COPD) Time: 13:30-15:10, November 5, 2011 (Saturday) Place: Room No. 1, 1st Floor, SCEC Session Chair Co-Chair 13:30-13:55 Dr. Andrzej Mariusz Fal, Professor & Chair, Department of Public Health, Wroclaw Medical University, Poland Dr. Amr El-Shazly, Professor of Rhinology, Liege University Hospital, Belgium Title: How Much Different is Asthma and COPD – Nearest Perspectives for New Therapies Dr. Andrzej Mariusz Fal, Professor & Chair, Department of Public Health, Wroclaw Medical University, Poland Title: CX3CR1 Receptor is a Novel Target for Therapeutic Modalities in Allergic Rhinitis Dr. Amr El-Shazly, Professor of Rhinology, Liege University Hospital, Belgium Title: Magic Role of Macrolides in COPD and Asthma. True or Myth? Dr. Ehsan Sabry, Professor, Asthma and Allergy Unit, Chest Department Kasr ALAini, Faculty of Medicine Cairo University, Egypt Title: Anti-Inflammatory & Anti-Asthmatic Natural Products from Medicinal Plants Dr. Sei-Ryang Oh, Principal Researcher; Director of Immune Modulator Research Center, Korea Research Institute of Bioscience & Biotechnology, Korea

13:55-14:20 14:20-14:45

14:45-15:10

Session 10-5: Severe Respiratory and Inflammation Diseases Session 10-5-2: Anti-Inflammatory Drugs Targeting Cytokine, Chemokine, NFkb, Toll-Like Receptors TNF, and Phosphodiesterases Time: 15:30-17:10, November 5, 2011 (Saturday) Place: Room No. 1, 1st Floor, SCEC Session Chair Co-Chair 15:30-15:55 15:55-16:20 Dr. Zhong Chen, Chief of Clinical Genomics Unit; Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, USA Dr. Tsutomu Akama, Research Leader, Medicinal Chemistry, Anacor Pharmaceuticals Inc., USA Title: Identification and SAR of AN6414, A Potent and Orally Active Benzoxaborole PDE4 Inhibitor Dr. Tsutomu Akama, Research Leader, Medicinal Chemistry, Anacor Pharmaceuticals Inc, USA Title: Targeting Caseine Kinase CK2 by Anti-CK2 Oligonucleotides via Sub-50nm Nanocapsules to Modulate NF-*B, TP53, And the Malignant Phenotype of Head and Neck Cancer Dr. Zhong Chen, Chief of Clinical Genomics Unit; Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, USA Title: Searching a Substrate for Denitrase, an Activity that Reduces Nitrotyrosine Immunoreactivity in Proteins Dr. Yasuyuki Irie, Associate Professor, Department of Pharmacology, Iwate Medical University, Japan Title: Expression Change of Nnicotinic Receptor by the Cell Maturity in the APC Cell Line Dr. Yukiko Kondo, Assistant Professor, Department of Pharmacology, Iwate Medical University, Japan

16:20-16:45

16:45-17:10

031

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 10-6: Autoimmune and Other Severe Immune Diseases Time: 13:30-15:10, November 5, 2011 (Saturday) Place: Room No. 2, 1st Floor, SCEC Session Chair Dr. Ole Haagen Nielsen, Professor, Faculty of Health Sciences, University of Copenhagen; Chief Physician, Department of Gastroenterology, Medical Section, Denmark Title: Biological Agents in Inflammatory bowel Disease(IBD): Current Concepts and Future Challenges Dr. Ole Haagen Nielsen, Professor, Faculty of Health Sciences, University of Copenhagen; Chief Physician, Department of Gastroenterology, Medical Section, Denmark Title: PPARgamma agonist as a Potential Therapeutic Agent for Neuropathic Pain Dr. Maiko Hasegawa-Moriyama, Assistant Professor, Kagoshima University, Japan Title: Novel Drug Applications in Immunologically-Related Fatigue Syndromes Dr. Donald R. Staines, Associate Professor, Queensland Health, Australia Title: Two Important Discoveries Dr. Nooshin Bagherani, Dermatologist, Valiasr Hospital, Iran

13:30-13:55

13:55-14:20 14:20-14:45 14:45-15:10

Session 10-7: Antimicrobial Resistance Drug Discovery Time: 13:30-15:35, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC Session Chair 13:30-13:55 13:55-14:20 14:20-14:45 14:45-15:10 Dr. Stephen Hawser, CEO, IHMA Europe Sàrl, Inc., Switzerland Title: Non-Antibiotic Strategies: Game-Changing Antibacterial Drug Discovery? Dr. Marc Lemonnier, CEO, ANTABIO SAS, Prologue Biotech Technopark Labege, France Title: Surveillance of Antibiotic Resistance Dr. Stephen Hawser, CEO, IHMA Europe Sàrl, Inc., Switzerland Title: Drug Discovery to Combat Antibiotic Resistance Dr. Eugénie Bergogne-Bérézin, Professor of the Universities, Consultant in Microbiology, France Title: Antiviral Therapy, If Detection of Polyomvirus in Cerebrospinal Fluid of Patients with Neurological Complications after Hematopoietic Stem Cell Transplantation Dr. Britt Gustafsson, Associate Professor, Department of Pediatrics, Karolinska University HospitalHuddinge, Sweden Title: A New Drugs Delivery Systems Containing Natural Products for Control and Treatment of Candidiasis/Mucositis in Irradiated Head and Neck Patients; Plaque, Gingivitis and Dental Caries Control Dr. Vagner Rodrigues Santos, Professor and Researcher, Faculty of Dentistry, University Federal of Minas Gerais (UFMG), Brazil

15:10-15:35

Session 10-8: Drug Resistant TB and Malaria Drug Discovery Time: 15:30-16:45, November 5, 2011 (Saturday) Place: Room No. 2, 1st Floor, SCEC Session Chair Co-Chair Dr. Alan Xiao, Director, Clinical Pharmacology & DMPK, AstraZeneca, USA Dr. Jan-Cedric Hansen, Medico-Marketing European Strategist at StratAdviser Ltd, Medical Coordinator at Hopital Asselin-Hedelin, France Title: Model-based Optimal Early Development of AZD5847, A New Anti-TB Drug Dr. Alan Xiao, Director, Clinical Pharmacology & DMPK, AstraZeneca, USA

15:30-15:55

032

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

15:55-16:20

16:20-16:45

Title: Literature Review on Current and Future Artemisinin-based Combination Therapy: Recent Trends Dr. Jan-Cedric Hansen, Medico-Marketing European Strategist at StratAdviser Ltd, Medical Coordinator at Hopital Asselin-Hedelin, France Title: Novel Multistage Strategies Against Malaria Dr. Miguel Prudêncio, Principal Investigator, Institute of Molecular Medicine, Portugal

Session 10-9: Novel Severe Virus Infectious Diseases Time: 15:55-16:45, November 5, 2011 (Saturday) Place: Room No. 3, 1st Floor, SCEC Session Chair Dr. Christopher W K Lam, Director of Pathology and Clinical Laboratory, University Hospital, Macau University of Science and Technology, Macau, China Title: A Clinical Study of Rorric for the Prevention and Treatment of Influenza A Infection Dr. Shiu Hon Chui, Associate Professor, Macau University of Science and Technology, Macau, China Title: New Strategies in Therapy and Drug Development of HIV Infection Dr. Nils von Hentig, Reader of Clinical Pharmacology and Senior House Officer, Johann Wolfgang Goethe University Hospital, Germany

15:55-16:20

16:20-16:45

Session 10-10: Cancer Drug Discovery and Development Time: 13:30-16:20, November 5, 2011 (Saturday) Place: Room No. 4, 1st Floor, SCEC Session Chair Dr. Dominic M. Desiderio, Professor, Department of Neurology, University of Tennessee Health Science Center, USA Title: Apaziquone – A Novel Drug in Late Stage Development for Bladder Cancer Dr. Rajesh C. Shrotriya, Chairman and CEO, Spectrum Pharmaceuticals, Inc., USA Title: The Nitroproteome of the Human Pituitary Dr. Dominic M. Desiderio, Professor, Department of Neurology, University of Tennessee Health Science Center, USA Title: Targeting of MDM2/XIAP Interaction for Cancer Drug Discovery Dr. Muxiang Zhou, Professor, Emory University School of Medicine, USA Title: Disruption of Hsp90 Function by Reactive Oxygen Species: A New Mechanism Explaining the Antitumoral Effects of Quinone Compounds Dr. Julien Verrax, Scientific Research Worker, Belgian National Fund for Scientific Research, Louvain Drug Research Institute, Catholic University of Louvain, Belgium Coffee Break Title: Intraperitoneal Chemotherapy Using Nano-Drug for Peritoneal Metastasis by Gastric Cancer Dr. Joji Kitayama, Associate Professor, Department of Surgical Oncology, The University of Tokyo, Japan Title: Carbon Ion Radiotherapy at Gunma University Dr. Tatsuya Ohno, Associate Professor, Gunma University Heavy Ion Medical Center, Gunma University, Japan

13:30-13:55 13:55-14:20

14:20-14:45 14:45-15:10

15:10-15:30 15:30-15:55

15:55-16:20

033

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Chapter 11: New Drug Bioprocess and Production under GMP Standards
Session 11-1: Cell Therapy and Cell Culture Processing Time: 13:30-14:20, November 5, 2011 (Saturday) Place: Room No. 5, 1st Floor, SCEC Session Chair Dr. Philippe R Henon, Professor, Cell Therapy at University of Haute Alsace, France; Director, the "Institut de Recherche en Hématologie et Transplantation", France Title: GMP Production of CD34+ Cell Grafts for Post-Infarct Myocardial Regeneration Dr. Philippe R Henon, Professor, Cell Therapy at University of Haute Alsace; Director, The "Research Institute of Hematology and Transplantation", France Title: Improved Separation Technologies for the Production of Biopharmaceuticals Dr. Emile van de Sandt, Principal Scientist, DSM Biotechnology Center, The Netherlands

13:30-13:55

13:55-14:20

Session 11-2: Rapid Production and Formulation Process of Biopharmaceuticals Time: 14:40-17:10, November 5, 2011 (Saturday) Place: Room No. 5, 1st Floor, SCEC Session Chair Dr. Crystal Jaing, Group Leader, Applied Genomics, Lawrence Livermore National Laboratory, USA Title: High Throughput Process Development Technologies and Their Application to Accelerate Early Stage Product Development Dr. Christopher Yallop, COO and CSO, Batavia Bioservices, the Netherlands Title: Pro and Cons of Dual Sourcing for Biopharmaceuticals Dr. Henri Kornmann, Director of Biotech Production, Merck Serono S.A., Switzerland Title: A Microbial Detection Array Applied to Vaccine Safety and Quality Control of Biologics Dr. Crystal Jaing, Group Leader, Applied Genomics, Lawrence Livermore National Laboratory, USA Title: Powder Products for Pulmonary or Intranasal Delivery Dr. Tom H. Jin, Scientist, Technique Operations/Manufacturing, Aeras Global TB Vaccine Foundation, USA Title: New Concept for Modern Design of Modular Vaccine Facilities Dr. Klaus Hermansen, Senior Specialist, Global Sales & Business Development, MSc Bio Engineering, NNE Pharmaplan, Denmark Title: High Yield Recombinant Production of Therapeutic Peptide Hormones for GPCRs Dr. Mohanraj Gopalswamy, Research Assistant, Institute of Physics/Biophysics, Martin-LutherUniversity of Halle-Wittenberg, Germany

14:40-15:05

15:05-15:30 15:30-15:55

15:55-16:20

16:20-16:45

16:45-17:10

Chapter 12: Me-too Drug Discovery and Biosimilars
Session 12-1: Me-Too Approaches to Improve Generic Drugs Time: 08:30-09:45, November 6, 2011 (Sunday) Place: Chrysanthemum Hall, 5th Floor, SCEC Session Chair 08:30-08:55 Dr. Daryl Fernandes, Chief Scientific Officer, Ludger Ltd., UK Title: Effective Ways to Significantly Improve the Clinical Performance and Costs of Biopharmaceuticals by Optimising Their Glycosylation Dr. Daryl L. Fernandes, Founder and CEO, Ludger Ltd., UK

034

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

08:55-09:20 09:20-09:45

Title: Protein Enzymatic Conjugation: A Robust Technology for Biobetter Preparation Dr. Giancarlo Tonon, General Manager, Bio-Ker s.r.l., Multimedica Group, Italy Title: Controversies Surrounding Non-Proprietary Low Molecular Weight Heparins Dr. Frederick A. Ofosu, Professor Emeritus, Department of Pathology & Molecular Medicine, Faculty of Health Sciences, McMaster University, Canada

Session 12-2: Opportunities and Challenges for Biosimilars in the Global Market Time: 10:30-12:10, November 6, 2011 (Sunday) Place: Chrysanthemum Hall, 5th Floor, SCEC Session Chair 10:30-10:55 10:55-11:20 11:20-11:45 11:45-12:10 Dr. Thomas Gelzleichter, Senior Scientist/ Group Leader ITGR, Genentech, Inc., USA Title: Nonclinical Safety Studies in Support of Biosimilars Development: Industry Perspective Dr. Thomas Gelzleichter, Senior Scientist/ Group Leader ITGR, Genentech, Inc., USA Title: Opportunities and Challenges for Biosimilars: A Closer Look at the Global Insulin Market Dr. Kelly Close, President, Close Concerns, Inc., USA Title: Biosimilars in the US: Not Gonna Happen Dr. Claudia Wiatr, Senior Principal, Wolters Kluwer Pharma Solutions, UK Title: US Biosimilars Patent Litigation Framework and Strategy Dr. Brian V. Slater, Partner, Fitzpatrick, Cella, Harper & Scinto Intellectual Property Law, USA

Session 12-3: Legal, Patent, Regulatory and Pharmacovigilance on Biosimilars Time: 08:30-10:10, November 6, 2011 (Sunday) Place: Peony Hall, 5th Floor, SCEC Session Chair 08:30-08:55 08:55-09:20 09:20-09:45 09:45-10:10 Dr. Kevin Murphy, Partner, Frommer Lawrence Haug LLP, USA Title: Approval Pathways for Biosimilars in the U.S. and EU Dr. Wendy Choi, Partner, Kilpatrick Townsend & Stockton LLP, USA Title: Biosimilars under Obamacare: Biologics Price Competition and Innovation Act of 2009 Dr. Kevin Murphy, Partner, Frommer Lawrence Haug LLP, USA Title: The Biosimilars Framework in Europe: Prosecution and Litigation Strategies Dr. Christine Kanz, Lawyer, Reimann Osterrieth Köhler Haft, Germany Title: Bioequivalence: What Does it Really Means Dr. Chong Chee Ping, Lecturer and Researcher, Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Malaysia

Chapter 13: Key Issues in IND Filing and Regulatory Approval Process
Session 13-1: Key Issues in IND Filing and Regulatory Approval Process Time: 08:30-10:35, November 6, 2011 (Sunday) Place: Rose 1 Hall, 5th Floor, SCEC Session Chair Co-Chair Dr. Beat Widler, Clinical Quality and Risk Management Expert, QAsperience, Switzerland Dr. Giovanni Dondi Dall’Orologio, Professor and Director, Division of Conservative Dentistry, University of Bologna, Italy Title: Quality Risk Management in Clinical Trials and Pharmacovigilance Dr. Beat Widler, Clinical Quality and Risk Management Expert, QAsperience, Switzerland Title: Orphan Drugs How They Change Both the R & D and Marketing Strategy of Pharma Companies Dr. Jan-Cedric Hansen, Director, International Medical&n, StratAdviser Ltd., France

08:30-08:55 08:55-09:20

035

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

09:20-09:45 09:45-10:10

10:10-10:35

Title: The Use of Social Media as a Strategy for Patient Recruitment and Retention in Clinical Trials Dr. Diana L. Anderson, President and CEO, D. Anderson & Company, USA Title: Understanding FDA’s Regulations and Policies in IND/NDA Review - A Key Successful Element for New Dug Development Dr. Yuanchao (Derek) Zhang, Vice President, Regulatory Affairs and Clinical Pharmacology, Frontage Laboratories, Inc. USA Title: CONSORT 2010 Statement: Updated Guidelines for Randomized Trials Dr. Giovanni Dondi Dall’Orologio, Professor and Director, Division of Conservative Dentistry, University of Bologna, Italy

Chapter 14: Drug Discovery Integrative Services, Deal-Making, and Business Development
Session 14-1: Drug Discovery Integrative Services, Deal-Making, and Business Development Time: 10:55-12:10, November 6, 2011 (Sunday) Place: Rose 1 Hall, 5th Floor, SCEC Session Chair Dr. Maosheng Duan, VP and Head of Medicinal Chemistry, HD Biosciences (China) Co., Ltd, China Title: Powering Drug Discovery Innovation in China, the CrownBio Story Dr. Sam Lou, Vice President, Business Development in Greater China Crown Biowcience. Inc., USA Title: Fill in Client’s Pipeline Gap with Medicinal Chemistry Service from HD Biosciences Dr. Maosheng Duan, VP and Head of Medicinal Chemistry, HD Biosciences (China) Co., Ltd, China Title: The Collaboration Models for Integrated Services CROs to Support Drug Discovery Dr. Chunlin Chen, CEO, Shanghai Medicilon Inc., China

10:55-11:20

11:20-11:45

11:45-12:10

Chapter 15: Drug Discovery R & D Management and Translational Medicine
Session 15-1: The Knowledge Management Process for Drug Discovery Time: 08:30-10:10, November 6, 2011 (Sunday) Place: Rose 2 Hall, 5th Floor, SCEC Session Chair 08:30-08:55 08:55-09:20 Dr. Raghu Raghavan, Partner and President, Therataxis LLC, USA Title: Learning and Knowledge Management in the Safety Arena Dr. Paul Beninger, Vice President, Global Patient Safety, Genzyme, USA Title: Delivering Therapy to Target: An Often Forgotten Chapter in Improving the Probability of Successful Drug Development Dr. Raghu Raghavan, Partner and President, Therataxis LLC, USA Title: Securing, Increasing and Catching Value in Translational Medicine A Case Study Dr. Bernd Eisele, CEO, Vakzine Projekt Management GmbH, Germany Title: Graphical Representation of the Assessment of Inventive Step Using the Problem-SolutionApproach ( PSA ) Dr. Joachim Stellmach, Directorate Advisor, European Patent Office, Germany

09:20-09:45 09:45-10:10

036

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Session 15-2: Biomarkers & Translational Medicine Time: 10:30-11:45, November 6, 2011 (Sunday) Place: Rose 2 Hall, 5th Floor, SCEC Session Chair 10:30-10:55 10:55-11:20 Dr. Richard May, Associate Director - Research, MedImmune Ltd, UK Title: Heterogeneity in Severe Asthma: Implications for Future Therapies Dr. Richard May, Associate Director - Research, MedImmune Ltd., UK Title: Driving Improved Clinical Outcomes with the Power of Illumina Next Generation Sequencing Technology Dr. Vanessa Tyrrell, Business Manager, Diagnostics, Illumina, Japan Title: More Efficient Drug Discovery Trials in Schizophrenia: Insights from 29 Placebo-Controlled Rcts of Second-Generation Antipsychotics in the Newmeds Repository Dr. Jonathan Rabinowitz, Professor, Bar Ilan University, Israel

11:20-11:45

Session 15-3: Anticancer Translational Medicine Time: 10:30-12:10, November 6, 2011 (Sunday) Place: Peony Hall, 5th Floor, SCEC Session Chair 10:30-10:55 10:55-11:20 11:20-11:45 Dr. Michael N. Liebman, President/Managing Director, Strategic Medicine, Inc, USA Title: From Bedside to Bench to Bedside Dr. Michael R. Briggs, Senior Director, Vertex Pharmaceuticals, Inc, USA Title: Translational Research, Bedside-to-Bench-to Bedside: Modeling Breast Cancer Dr. Michael N. Liebman, Managing Director, Strategic Medicine, Inc and BV, USA Title: BINET Business Intelligence for Social Network Analysis, Case Study in Healthcare Field Dr. Sabrina Molinaro, Head, Epidemiology and Health Research Department, Institute for Clinical Physiology, National Research Council, Italy Title: Using Genetically Defined Cell Lines to Predict Resistance to Targeted Cancer Therapies in Patients Dr. Rob Howes, R & D Director, Horizon Discovery, UK

11:45-12:10

Special Symposia on Non-Human Drug Discovery
Special Symposia on Non-Human Drug Discovery Time: 08:30-09:20, November 6, 2011 (Sunday) Place: Rose 3 Hall, 5th Floor, SCEC Session Chair 08:30-08:55 08:55-09:20 Dr. Marcus Remmers, Head of Pharmaceutical R & D, Merial Limited, USA Title: Animal Health Discovery and Licensing Dr. Marcus Remmers, Head of Pharmaceutical R & D, Merial Limited, USA Title: Control of Emerging Infectious Diseases: Novel Targets and Vaccine Formulations Dr. Andrew A. Potter, Director and CEO, Vaccine and Infectious Disease Organization, International Vaccine Centre, Canada

037

BIT's 9th Annual Congress of International Drug Discovery Science and Technology

Shenzhen * China

Poster Presentation Session
Poster Presentation Session Time: 13:30-15:00, November 4, 2011 (Friday) Place: Room No. 9, 1st Floor, SCEC Session Chair 13:30-13:45 13:45-14:00 Dr. Fabio Fazzi, University of Bologna, Italy Title: Non Inferiority Trials Dr. Fabio Fazzi, University of Bologna, Italy Title: Improving Poor Orally Bioavailable Drugs by Sublingual Administration—Example with Propronolol Dr. Zhijun Wang, Research Associate, School of Pharmacy, Chinese University of Hong Kong, China Title: Activators of MRP1 as Anti-cancer Agents Targeting Chemoresistant Cancer Cells Ms. Doriane Lorendeau, Drug Resistance Mechanism and Modulation, University Lyon 1, France Title: Treatment of Halogen Bonding by Current Biomolecular Empirical Mr. Michal Kolar, Institute of Organic Chemistry and Biochemistry, Czech Republic Title: Amelioration of Atopic Dermatitis Model in Mice by NF-B Inhibitor DHMEQ and its Mechanism of Action Ms. Kana Horie, Center for Chemical Biology, Faculty of Science and Technology, Keio University, Japan Title: Isolation and Screening of Actinobacteria and Proteobacteria from Antarctic Soil for Antimicrobial Metabolites Mr. Lee Learn Han, Universiti Putra Malaysia, Malaysia

14:00-14:15 14:15-14:30 14:30-14:45

14:45-15:00

038